No headlines found.
Ascentage Pharma to Present at 44th Annual J.P. Morgan Healthcare Conference
Globe Newswire (Wed, 17-Dec 8:00 AM ET)
Globe Newswire (Mon, 8-Dec 7:45 PM ET)
Globe Newswire (Mon, 8-Dec 7:45 PM ET)
Globe Newswire (Mon, 8-Dec 7:45 PM ET)
Globe Newswire (Sun, 7-Dec 8:10 PM ET)
Globe Newswire (Sat, 6-Dec 10:15 AM ET)
Globe Newswire (Thu, 4-Dec 7:00 PM ET)
Ascentage Pharma to Host Webcast Highlighting Key Data from ASH 2025
Globe Newswire (Mon, 1-Dec 8:00 AM ET)
Globe Newswire (Mon, 24-Nov 7:00 PM ET)
Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025
Globe Newswire (Wed, 19-Nov 8:00 AM ET)
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.
Ascentage Pharma Group International - American Depository Shares trades on the NASDAQ stock market under the symbol AAPG.
As of December 24, 2025, AAPG stock price was flat at $27.88 with 172 million shares trading.
AAPG has a market cap of $2.59 billion. This is considered a Mid Cap stock.
AAPG support price is $26.27 and resistance is $29.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AAPG shares will trade within this expected range on the day.
